3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Esophageal Squamous Cell Carcinoma
5
Neoplasm Metastasis
4
Carcinoma, Hepatocellular
4
Advanced Solid Tumors
4
Recurrence
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Solid Tumors
1
Sarcoma
1
Neuroendocrine Tumors
1
Nasopharyngeal Neoplasms
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Locally Advanced or Metastatic Urothelial Bladder Cancer
1
Interventions
pembrolizumab
4
Cisplatin
4
Gemcitabine
3
Carboplatin
3
Docetaxel
2
Bupropion
2
tocilizumab
1
tislelizumab
1
spartalizumab
1
infigratinib
1
etoposide phosphate
1
cc-486
1
avelumab
1
Zoledronic Acid
1
Vorinostat
1
Varenicline
1
Tobacco Use Cessation Devices
1
Radiotherapy, Intensity-Modulated
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Pilocarpine
1
Oral Hygiene
1
Nivolumab
1
Nicotine Replacement Therapy
1
Nicotine
1
NVP-BKM120
1
Ifosfamide
1
Gene Expression Profiling
1
Fluorouracil
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Nasopharyngeal Neoplasms
×
tislelizumab
×
Clear all
NCT03924986
2025-01-31
RATIONALE-309
BeiGene
Phase 3
Completed
263 enrolled
19 charts